Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05952583 · ClinicalTrials.gov registry record
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
A clinical trial of Fetal Growth Retardation and Twin; Pregnancy, Affecting Fetus or Newborn, sponsored by Leiden University Medical Center.
- Recruiting
- Registry status
- 274
- Enrollment target
- 6
- Study locations
NCT05952583: Recruiting study of Fetal Growth Retardation and Twin; Pregnancy, Affecting Fetus or Newborn, sponsored by Leiden University Medical Center.
NCT05952583 is a study of Fetal Growth Retardation and Twin; Pregnancy, Affecting Fetus or Newborn that is actively recruiting participants, run by Leiden University Medical Center. The registered enrollment target is 274 participants, below the 414-participant average among 3 other Fetal Growth Retardation trials with a reported enrollment target (34% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05952583, a study of Fetal Growth Retardation and Twin; Pregnancy, Affecting Fetus or Newborn, is actively recruiting participants, sponsored by Leiden University Medical Center.
- RECRUITING
- Registry status
- 274 participants
- Enrollment target
- 6
- Study locations
Study Summary
Optimal diagnostic management and underlying pathophysiological mechanisms of selective fetal growth restriction (sFGR) in monochorionic diamniotic (MCDA) twin pregnancies have not been fully clarified. The current diagnostic classification system based on three different umbilical artery flow patterns has no increasing scale of severity and the predictive value is limited. Since there is no treatment available for sFGR, predicting fetal deterioration is key in preventing single or double fetal demise. Outcome prediction is furthermore important in the selection of cases that will be offered selective reduction (to provide the larger twin with better prospects), as well as determining monitor frequency and possible hospital admission. As outcome prediction is clinically challenging, patient counselling is too, and parents often encounter a great deal of uncertainty during the pregnancy. Furthermore, little is known about the brain development of sFGR children (both during pregnancy and after birth). Moreover, the psychological impact of an sFGR pregnancy of the future parent)s) has not been studied before. The impact of these factors should be taken into account during patient counseling, which is currently not the case. By our knowledge, this is the first international, multicenter, prospective cohort study on that will address the abovementioned questions and knowledge gaps in MCDA pregnancies complicated by selective fetal growth restriction.
Primary Outcome
The composite outcome consists of fetal single or double demise, including selective fetal reduction and/or an iatrogenic elective birth \< 32 weeks of gestational age because of fetal distress).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Ultrasound
Study Locations (6)
Other
- Universitaire Ziekenhuizen Leuven - Leuven
- BCNatal - Barcelona
- Karolinska University Hospital - Stockholm
Massachusetts
- Boston Children's Hospital - Boston
Ontario
- Mount Sinai Hospital - Toronto
South Holland
- Leiden University Medical Center - Leiden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2023-02-17 |
| Est. Completion | 2028-03-01 |
What NCT05952583 shows while recruiting
NCT05952583 is an observational study that tracks outcomes without assigning an intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, below the 414-participant average among 3 other Fetal Growth Retardation trials with a reported enrollment target (34% lower).
The record links to 4 conditions, with Fetal Growth Retardation appearing as the primary indexed condition, and to 1 intervention - of which Ultrasound is the first listed.
NCT05952583 lists 6 locations in 4 states (Other, Massachusetts, Ontario).
Frequently Asked Questions
What is clinical trial NCT05952583 about?
NCT05952583 is a clinical study titled "Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation". Optimal diagnostic management and underlying pathophysiological mechanisms of selective fetal growth restriction (sFGR) in monochorionic diamniotic (MCDA) twin pregnancies have not been fully clarified. The current diagnostic classification system based on three different umbilical artery flow patt...
What is the current status of trial NCT05952583?
This trial is currently recruiting. The enrollment target is 274 participants. The study started on 2023-02-17. Estimated completion is 2028-03-01.
What conditions does trial NCT05952583 study?
This clinical trial studies the following conditions: Fetal Growth Retardation, Twin; Pregnancy, Affecting Fetus or Newborn, Twin Monochorionic Diamniotic Placenta, Twin Diseases.
What interventions are being tested in trial NCT05952583?
The interventions under investigation include: Ultrasound (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05952583?
This trial is sponsored by Leiden University Medical Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05952583 being conducted?
This trial has 6 study locations across Massachusetts, Ontario, South Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fetal Growth Retardation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
- NCT06173401 · 274 participants · Phase 3
Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI